Site Map

Homocystinuria

Cystathionine beta-synthase deficiency; CBS deficiency; HCY

Homocystinuria is a genetic disorder that affects the metabolism of the amino acid methionine. Amino acids are the building blocks of all proteins in the body.

Images

Pectus excavatum

Causes

Homocystinuria is inherited in families as an autosomal recessive trait. This means that the child must inherit a non-working copy of the gene from each parent to be seriously affected.

People with homocystinuria have several physical features in common with Marfan syndrome, including skeletal and eye changes.

Symptoms

Newborn infants appear healthy. Early symptoms, if present, are not obvious.

Symptoms may occur as mildly delayed development or failure to thrive. Increasing visual problems may lead to diagnosis of this condition.

Other symptoms include:

Exams and Tests

The health care provider may notice that the child is tall and thin.

Other signs include:

If there is poor or double vision, an eye doctor (ophthalmologist) will perform a dilated eye exam to look for dislocation of the lens or nearsightedness.

There may be a history of blood clots. Intellectual disability or mental illness is also possible.

Tests that may be ordered include any of the following:

Treatment

There is no cure for homocystinuria. About half of people with the disease respond to vitamin B6 (also known as pyridoxine).

Those who do respond will need to take vitamin B6, B9 (folate), and B12 supplements for the rest of their lives. Those who do not respond to supplements will need to eat a low-methionine diet. Most will need to be treated with trimethylglycine (a medicine also known as betaine).

Neither a low-methionine diet nor medicine will improve existing intellectual disability. Medicine and diet should be closely monitored by a doctor who has experience treating homocystinuria.

Support Groups

More information and support for people with homocystinuria and their families can be found at:

Outlook (Prognosis)

Although no cure exists for homocystinuria, vitamin B therapy can help about half of people affected by the condition.

If the diagnosis is made in childhood, starting a low-methionine diet quickly may prevent some intellectual disability and other complications of the disease. For this reason, some states screen for homocystinuria in all newborns.

People whose blood homocysteine levels continue to rise are at increased risk for blood clots. Clots can cause serious medical problems and shorten lifespan.

Possible Complications

Most serious complications occur due to blood clots. These episodes can be life threatening.

Dislocated lenses of the eyes can seriously damage vision. Lens replacement surgery may be needed.

Intellectual disability is a serious outcome of the disease. But, it can be reduced if diagnosed early.

When to Contact a Medical Professional

Contact your provider if you or a family member shows symptoms of this disorder, especially if you have a family history of homocystinuria.

Prevention

Genetic counseling is recommended for people with a family history of homocystinuria who want to have children. Prenatal diagnosis of homocystinuria is available. This involves culturing amniotic cells or chorionic villi to test for cystathionine synthase (the enzyme that is missing in homocystinuria).

If there are known gene conditions in the parents or family, samples from chorionic villus sampling or amniocentesis can be used to test for these defects before a baby is born.

Related Information

Metabolism
Autosomal recessive
Nearsightedness
Dislocation
Blood clots
Failure to thrive
Vision problems
Intellectual disability
Marfan syndrome
Arachnodactyly
High arch
Knock knees
Scoliosis

References

Schiff M, Blom HJ. Homocystinuria and hyperhomocysteinemia. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 193.

Shchelochkov OA, Venditti CP. Methionine./Defects in metabolism of amino acids. In: Kliegman RM, St. Geme JW, Blum NJ, et al, eds. Nelson Textbook of Pediatrics. 22nd ed. Philadelphia, PA: Elsevier; 2025:chap 105.1.

BACK TO TOP

Review Date: 12/31/2023  

Reviewed By: Anna C. Edens Hurst, MD, MS, Associate Professor in Medical Genetics, The University of Alabama at Birmingham, Birmingham, AL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

ADAM Quality Logo
Health Content Provider
06/01/2025

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complied with the HONcode standard for trustworthy health information from 1995 to 2022, after which HON (Health On the Net, a not-for-profit organization that promoted transparent and reliable health information online) was discontinued.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2024 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.